New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect

Physica Medica

Volumn 31, Issue 1, 2015, Pages 25-30

  Altundal, Yucel ^a   Cifter, Gizem ^a   Detappe, Alexandre ^b,c   Sajo, Erno ^a   Tsiamas, Panagiotis ^b   Zygmanski, Piotr ^b   Berbeco, Ross ^b   Cormack, Robert A ^b   Makrigiorgos, Mike ^b   Ngwa, Wilfred ^a,b  

^a University of Massachusetts Lowell   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

Brachytherapy; Chemoradiotherapy; Cisplatin nanoparticles; Dose enhancement; Radiotherapy

Indexed keywords

BIOMATERIAL; CISPLATIN; NANOPARTICLE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL; CHEMORADIOTHERAPY; DRUG RELEASE; EXTERNAL BEAM RADIOTHERAPY; FOOD AND DRUG ADMINISTRATION; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MONTE CARLO METHOD; PREDICTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOSENSITIZATION; TUMOR VOLUME; BRACHYTHERAPY; DOSE RESPONSE; DRUG APPROVAL; ELECTRON; HUMAN; LIGHT; NEOPLASMS; PROCEDURES; RADIOTHERAPY DOSAGE; UNITED STATES;

ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CHEMORADIOTHERAPY; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; ELECTRONS; HUMANS; LIGHT; NEOPLASMS; RADIOTHERAPY DOSAGE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84927696564     PISSN: 11201797     EISSN: 1724191X     Source Type: Journal    
DOI: 10.1016/j.ejmp.2014.11.004     Document Type: Article

References (42)

1. Seiwert T.Y., Salama J.K., Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 2007, 4:86-100.
2. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy invivo 2010.
3. Zheng Y., Hunting D., Ayotte P., Sanche L. Role of secondary low-energy electrons in the concomitant chemoradiation therapy of cancer. Phys Rev Lett 2008, 100:198101.
4. Wilson G.D., Bentzen S.M., Harari P.M. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006, 16:2-9.
5. Cooper D.R., Bekah D., Nadeau J.L. Gold nanoparticles and their alternatives for radiation therapy enhancement. Front Chem 2014, 2:86.
6. Marcu L., Bezak E. Stochastic modelling of the role of cisplatin in altered fractionation schedules for head and neck cancer. Phys Med 2010, 26:177-183.
7. Cheung J.Y.C., Tang F. The calculation of dose enhancement close to platinum implants for skull radiography. Health Phys 2007, 93:267-272.
8. Rousseau J., Barth R.F., Fernandez M., Adam J.-F., Balosso J., Estève F., et al. Efficacy of intracerebral delivery of cisplatin in combination with photon irradiation for treatment of brain tumors. JNeurooncol 2010, 98:287-295.
9. Taratula O., Garbuzenko O.B., Chen A.M., Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. JDrug Target 2011, 19:900-914.
10. Peng X.-H., Wang Y., Huang D., Wang Y., Shin H.J., Chen Z., et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano 2011, 5:9480-9493.
11. Cormack R.A., Sridhar S., Suh W.W., D'Amico A.V., Makrigiorgos G.M. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. Int J Radiat Oncol Biol Phys 2010, 76:615-623.
12. Nagesha D.K., Tada D.B., Stambaugh C.K.K., Gultepe E., Jost E., Levy C.O., et al. Radiosensitizer-eluting nanocoatings on gold fiducials for biological in-situ image-guided radio therapy (BIS-IGRT). Phys Med Biol 2010, 55:6039-6052.
13. Berbeco R.I., Ngwa W., Makrigiorgos G.M. Localized dose enhancement to tumor blood vessel endothelial cells via megavoltage X-rays and targeted gold nanoparticles: new potential for external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 81:270-276.
14. Ngwa W., Makrigiorgos G.M., Berbeco R.I. Applying gold nanoparticles as tumor-vascular disrupting agents during brachytherapy: estimation of endothelial dose enhancement. Phys Med Biol 2010, 55:6533-6548.
15. Kuban D.A., Levy L.B., Cheung M.R., Lee A.K., Choi S., Frank S., et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys 2011, 79:1310-1317.
16. Cho S.H., Jones B.L., Krishnan S. The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/x-ray sources. Phys Med Biol 2009, 54:4889-4905.
17. Elbialy N.S., Fathy M.M., Khalil W.M. Preparation and characterization of magnetic gold nanoparticles to be used as doxorubicin nanocarriers. Phys Med 2014, 30:843-848.
18. Detappe A., Tsiamas P., Ngwa W., Zygmanski P., Makrigiorgos M., Berbeco R. The effect of flattening filter free delivery on endothelial dose enhancement with gold nanoparticles. Med Phys 2013, 40:031706.
19. Liu H.H., Verhaegen F. An investigation of energy spectrum and lineal energy variations in mega-voltage photon beams used for radiotherapy. Radiat Prot Dosimetry 2002, 99:425-427.
20. Cole A. Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res 1969, 38:7-33.
21. Bennington J.L. Cellular kinetics of invasive squamous carcinoma of the human cervix cellular kinetics of invasive squamous carcinoma 1969, 1082-1088.
22. Boulikas T. Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 2009, 18:1197-1218.
23. Sacco J.J., Botten J., Macbeth F., Bagust A., Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 2010, 5:e8933.
24. Eichelberger M.D.L.E., Koch M.D.M.O., Daggy M.S.J.K., Ulbright M.D.T.M., Eble M.D.J.N., Cheng M.D.L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 2003, 120:386-391.
25. Flieder D.B., Port J.L., Korst R.J., Christos P.J., Levin M.a., Becker D.E., et al. Tumor size is a determinant of stage distribution in t1 non-small cell lung cancer. Chest 2005, 128:2304-2308.
26. Song H., Du Y., Sgouros G., Prideaux A., Frey E., Wahl R.L. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. JNucl Med 2007, 48:150-157.
27. Keall P.J., Mageras G.S., Balter J.M., Emery R.S., Forster K.M., Jiang S.B., et al. The management of respiratory motion in radiation oncology report of AAPM task group 76. Med Phys 2006, 33:3874.
28. Machtay M., Bae K., Movsas B., Paulus R., Gore E.M., Komaki R., et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2012, 82:425-434.
29. Sengupta P., Basu S., Soni S., Pandey A., Roy B., Oh M.S., et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 2012, 109:11294-11299.
30. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A.G., Ithakissios D.S. PLGA-mPEG nanoparticles of cisplatin: invitro nanoparticle degradation, invitro drug release and invivo drug residence in blood properties. JControl Release 2002, 79:123-135.
31. Dong Y., Chin S.-F., Blanco E., Bey E.a., Kabbani W., Xie X.-J., et al. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 2009, 15:131-139.
32. Qian F., Szymanski A., Gao J. Fabrication and characterization of controlled release poly(D,L-lactide-co-glycolide) millirods. JBiomed Mater Res 2001, 55:512-522.
33. Mady M.M., Fathy M.M., Youssef T., Khalil W.M. Biophysical characterization of gold nanoparticles-loaded liposomes. Phys Med 2012, 28:288-295.
34. Kim Y., Tomé W.A. Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans. Acta Oncol (Madr) 2008, 47:906-916.
35. Chattopadhyay N., Cai Z., Kwon Y.L., Lechtman E., Pignol J.P., Reilly R.M. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation. Breast Cancer Res Treat 2013, 137:81-91.
36. Chattopadhyay N., Cai Z., Pignol J.-P., Keller B., Lechtman E., Bendayan R., et al. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer. Mol Pharm 2010, 7:2194-2206.
37. Chithrani D.B., Jelveh S., Jalali F., van Prooijen M., Allen C., Bristow R.G., et al. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res 2010, 173:719-728.
38. Cai Z., Pignol J.-P., Chattopadhyay N., Kwon Y.L., Lechtman E., Reilly R.M. Investigation of the effects of cell model and subcellular location of gold nanoparticles on nuclear dose enhancement factors using Monte Carlo simulation. Med Phys 2013, 40:114101.
39. Wälzlein C., Scifoni E., Krämer M., Durante M. Simulations of dose enhancement for heavy atom nanoparticles irradiated by protons. Phys Med Biol 2014, 59:1441-1458.
40. Wälzlein C., Krämer M., Scifoni E., Durante M. Advancing the modeling in particle therapy: from track structure to treatment planning. Appl Radiat Isot 2014, 83. Pt B:171-6.
41. Douglass M., Bezak E., Penfold S. Monte Carlo investigation of the increased radiation deposition due to gold nanoparticles using kilovoltage and megavoltage photons in a 3D randomized cell model. Med Phys 2013, 40:071710.
42. Shikanov A., Shikanov S., Vaisman B., Golenser J., Domb A.J. Cisplatin tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant. Chemother Res Pract 2011, 2011:175054.